Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compounds and uses in treating infectious diseases viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Abstract: Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives of clevudine in combination with another antiviral agent. The compounds and compositions include derivatives of clevudine in combination with a phosphoramnidate of lamivudine, adefovir, tenofovir, telbivudine, entecavir, or combinations thereof.

Abstract: Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives of clevudine in combination with another antiviral agent. The compounds and compositions include derivatives of clevudine in combination with a phosphoramidate of lamivudine, adefovir, tenofovir, telbivudine, entecavir, or combinations thereof.

Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below,

Abstract: The present invention relates to methods for processing jobs within a cluster architecture. One method comprises the pausing of a job when waiting upon external dependencies. Another method comprises the transmission of messages relating to the ongoing processing of jobs back to a client via a persistent messaging channel. Yet another method comprises determining capacity at a node before allocating a job for processing by the node or adding the job to a cluster queue. A system for processing jobs within a cluster architecture is also disclosed.

Abstract: The present invention relates to methods for processing jobs within a cluster architecture. One method comprises the pausing of a job when waiting upon external dependencies. Another method comprises the transmission of messages relating to the ongoing processing of jobs back to a client via a persistent messaging channel. Yet another method comprises determining capacity at a node before allocating a job for processing by the node or adding the job to a cluster queue. A system for processing jobs within a cluster architecture is also disclosed.

Abstract: Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives of clevudine in combination with another antiviral agent. The compounds and compositions include derivatives of clevudine in combination with a phosphoramidate of lamivudine, adefovir, tenofovir, telbivudine, entecavir, or combinations thereof.

Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.

Abstract: The present invention relates to methods for processing jobs within a cluster architecture. One method comprises the pausing of a job when waiting upon external dependencies. Another method comprises the transmission of messages relating to the ongoing processing of jobs back to a client via a persistent messaging channel. Yet another method comprises determining capacity at a node before allocating a job for processing by the node or adding the job to a cluster queue. A system for processing jobs within a cluster architecture is also disclosed.

Abstract: The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a variety of medical disorders, in particular viral infections, cancers and the like.

Abstract: The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

Abstract: The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions are provided that include an antiviral lipid-containing compound, or salt, ester, or prodrug thereof and one or more bioavailability enhancing compounds, such as inhibitors of cytochrome P450 enzymes.

Abstract: This application provides a process for preparing enantiomerically pure ?-D-dioxolane nucleosides. In particular, a new synthesis of (?)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure ?-D- or ?-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected ?-D- or P-L-1,3-dioxolane nucleoside.